Raymond James Financial Services Advisors’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Raymond James Financial Services Advisors’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$3.79M	Buy	84,301 +1,678	+2%	+$75K	0.01%	1384
2024 Q2	$3.45M	Buy	82,623 +16,791	+26%	+$702K	﹤0.01%	1358
2024 Q1	$3M	Buy	65,832 +3,085	+5%	+$141K	﹤0.01%	1428
2023 Q4	$2.9M	Buy	62,747 +5,203	+9%	+$212K	﹤0.01%	1370
2023 Q3	$2.34M	Buy	57,544 +19,541	+51%	+$890K	﹤0.01%	1412
2023 Q2	$1.84M	Buy	38,003 +4,546	+14%	+$227K	﹤0.01%	1556
2023 Q1	$1.65M	Buy	33,457 +8,243	+33%	+$424K	﹤0.01%	1604
2022 Q4	$1.28M	Buy	25,214 +3,311	+15%	+$171K	﹤0.01%	1687
2022 Q3	$1.1M	Sell	21,903 -888	-4%	-$50.1K	﹤0.01%	1750
2022 Q2	$1.11M	Buy	+22,791	New	+$1.16M	﹤0.01%	1761
2022 Q1	–	Sell	-3,559	Closed	-$283K	–	3379
2021 Q4	$283K	Sell	3,559 -591	-14%	-$49.6K	﹤0.01%	2756
2021 Q3	$368K	Buy	+4,150	New	+$389K	﹤0.01%	2559

Other funds holding GNOM

OCM

One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Mirae Asset Global ETFs Holdings Causeway Bay, Hong Kong $73.7B AUM 53.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Lido Advisors Los Angeles, California $32.7B AUM 19.2% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Krilogy Financial St. Louis, Missouri $3.11B AUM 20.67% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

Raymond James Financial Services Advisors's GNOM Position: Q3 2024 in Review

Raymond James Financial Services Advisors increased its Global X Genomics & Biotechnology ETF (GNOM) stake by 2% in Q3 2024, buying an estimated $75K and bringing the position to 84,301 shares worth $3.79M. The position accounts for 0.01% of the portfolio, ranked #1384.

Raymond James Financial Services Advisors first reported a position in GNOM in Q3 2021 and has held it in 12 quarters since. 64 funds tracked by Wall St. Rank hold GNOM as of Q3 2024.

Raymond James Financial Services Advisors held 84,301 shares of Global X Genomics & Biotechnology ETF worth $3.79M as of Q3 2024.
Raymond James Financial Services Advisors bought 1,678 Global X Genomics & Biotechnology ETF shares in Q3 2024, an estimated $75K.
Global X Genomics & Biotechnology ETF made up 0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #1384 holding.
Raymond James Financial Services Advisors first reported a position in Global X Genomics & Biotechnology ETF in Q3 2021 and has held it in 12 quarters since.
64 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.